|
?:abstract
|
-
COVID-19 has changed the nature of medical consultations, emphasizing virtual patient counseling, with relevance for patients with diabetes insipidus (DI) or hyponatraemia The main complication of desmopressin treatment in DI is dilutional hyponatraemia Since plasma sodium monitoring is not always possible in times of COVID-19, we recommend to delay the desmopressin dose once a week until aquaresis occurs allowing excess retained water to be excreted Patients should measure their body weight daily Patients with DI admitted to the hospital with COVID-19 have a high risk for mortality due to volume depletion Specialists must supervise fluid replacement and dosing of desmopressin Patients after pituitary surgery should drink to thirst and measure their body weight daily to early recognize the development of the postoperative syndrome of inappropriate antidiuresis (SIAD) They should know hyponatraemia symptoms The prevalence of hyponatraemia in patients with pneumonia due to COVID-19 is not yet known, but seems to be low In contrast, hypernatraemia may develop in COVID-19 patients in ICU, from different multifactorial reasons, for example, due to insensible water losses from pyrexia, increased respiration rate and use of diuretics Hypernatraemic dehydration may contribute to the high risk of acute kidney injury in COVID-19 IV fluid replacement should be administered with caution in severe cases of COVID-19 because of the risk of pulmonary oedema
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}